Coherus: Udenyca Trajectory ‘Unknown’ But ‘Compelling’ With On-Body Launch
As Firm Announces Another Round Of Layoffs, Including From Sandoz Divestment
Coherus BioSciences has spoken in detail about its full suite of Udenyca pegfilgrastim biosimilar products and how it plans to return to growth and positive cash flow moving forward – although it cannot, for now, provide an estimate for 2024 revenues.
